CoChat
Sign Up
Cited by 143Obstructive Sleep Apnea ResearchSinusitis and nasal conditionsSleep and related disorders

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Antiinflammatory Therapy Outcomes for Mild OSA in Children

Open access
Kheirandish-Gozal, Leila, Bhattacharjee, Rakesh, Bandla, Hari P.R., Gozal, David·2014·Chest
DOI 10.1378/chest.13-2288PMC PMC4077412
Open this paper in CoChat — free accountOpen PDF

Abstract

Background OSA is highly prevalent in children and usually initially treated by adenotonsillectomy. Nonsurgical alternatives for mild OSA primarily consisting of antiinflammatory approaches have emerged, but their efficacy has not been extensively assessed.Methods A retrospective review of clinically and polysomnographically diagnosed patients with OSA treated between 2007 and 2012 was performed to identify otherwise healthy children ages 2 to 14 years who fulfilled the criteria for mild OSA and who were treated with a combination of intranasal corticosteroid and oral montelukast (OM) for 12 weeks (ICS + OM). A subset of children continued OM treatment for 6 to 12 months.Results A total of 3,071 children were diagnosed with OSA, of whom 836 fulfilled mild OSA criteria and 752 received ICS + OM. Overall, beneficial effects occurred in > 80% of the children, with nonadherence being documented in 61 children and adenotonsillectomy being ultimately performed in 12.3%. Follow-up polysomnography in a subset of 445 patients showed normalization of sleep findings in 62%, while 17.1% showed either no improvement or worsening of their OSA. Among the latter, older children (aged > 7 years; OR, 2.3; 95% CI, 1.43-4.13; P < .001) and obese children (BMI z-score > 1.65; OR: 6.3; 95% CI, 4.23-11.18; P < .000001) were significantly more likely to be nonresponders.Conclusions A combination of ICS + OM as initial treatment of mild OSA appears to provide an effective alternative to adenotonsillectomy, particularly in younger and nonobese children. These results support implementation of multicenter randomized trials to more definitively establish the role of ICS + OM treatment in pediatric OSA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1378/chest.13-2288

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Medical treatment for pediatric OSA has been proposed, including nasal steroids and oral montelukast.

    “As an alternative to T&A for treatment of pediatric OSA, medical treatment has been proposed including nasal steroids and oral montelukast.2123–2125”

    From International Consensus Statement on Obstructive Sleep Apnea (2023) · cites this paper as [2123]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Metadata

Authors
Kheirandish-Gozal, L., Bhattacharjee, R., Bandla, H. P. R., & Gozal, D.
Affiliations
University of Chicago (US)
ORCID
Bhattacharjee, Rakesh
Venue
Chest
Publisher
Elsevier BV
Published
2014-07
Volume
146
Issue
1
Pages
88-95
ISSN
0012-3692 (ISSN-L)
DOI
10.1378/chest.13-2288
PMC
PMC4077412
OpenAlex
W2031192973
Semantic Scholar
ef15127a5be0f2bc2996bb3f21a53a25dfdc2557
Cited by
143
References
40
Citations by year
2026: 6 · 2025: 12 · 2024: 9 · 2023: 9 · 2022: 7 · 2021: 15 · 2020: 16 · 2019: 15 · 2018: 15 · 2017: 13 · 2016: 10 · 2015: 9 · 2014: 5
FWCI
8.20
Type
journal article
Language
en
Open access
Licence
Locations
  • CHEST Journal (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute (R01HL086662, P50HL107160, R01HL065270)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Obstructive Sleep Apnea Research
  • Health Sciences › Medicine › Otorhinolaryngology › Sinusitis and nasal conditions
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
Keywords
pediatric obstructive sleep apnea, mild sleep apnea, anti-inflammatory therapy, intranasal corticosteroids, montelukast, treatment non-adherence, predictors of treatment response, childhood obesity, polysomnography outcomes
MeSH terms
Adolescent, Anti-Inflammatory Agents, Child, Child, Preschool, Female, Follow-Up Studies, Humans, Male, Quality of Life, Retrospective Studies, Severity of Illness Index, Treatment Outcome, Polysomnography, Sleep Apnea, Obstructive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review